Hatanaka et al. [43], in the retrospective study that involved the largest number of patients undergoing c-b-TACE (66 patients), reported Grade 3 elevation of total bilirubin (6.1%) and ALT (9.1%), leukocytopenia (12.1%) and thrombocytopenia (7.6%), all managed with conservative therapy. This evidence concerns the gene GPT and Thrombocytopenia.